Quantcast

Got Stocks from QualityStocks Ones To Watch

Got Stocks

Find out which Small-Cap / Micro-Caps should be on your radar. Get the news and information that moves the markets this week and the "Ones to Watch", only at QualityStocks. The "Quality" is Back in Stocks...




Untitled Document

Interleukin Genetics, Inc. (ILIU)

Interleukin Genetics, Inc. develops and markets proprietary genetic tests for chronic diseases and health related conditions. It takes advantage of its research, intellectual property (IP), and genetic panel development expertise in metabolism and inflammation to facilitate the growing personalized healthcare market. Listed on the OTCQB, Interleukin Genetics is based in Waltham, Massachusetts.

Interleukin Genetics has two primary focus areas to its business. One is personalized health, focused on providing genetic information to physicians, dentists, and in some cases consumers. The second is a research and development (R&D) effort focused on developing genetic tests linked to a partner's products for marketing and sales into medical and dental channels.

The company markets its tests via partnerships with health and wellness companies, healthcare professionals, and other distribution channels. It operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Amendments (CLIA).

Interleukin's products encourage individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. The company's flagship products include its proprietary PerioPredict® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health® Weight Management Genetic Test, which identifies the most effective diet and exercise program for an individual based on genetics.

Interleukin Genetics has been granted a patent by the European Patent Office (EPO) covering its Inherent Health® Weight Management Genetic Test. The granted patent, entitled "Genetic Markers for Weight Management and Methods of Use Thereof," has claims covering methods of determining a subject's metabolic genotype and methods for selecting an appropriate therapeutic/dietary regimen or lifestyle recommendation based on the subject's metabolic profile and susceptibility to adverse weight management issues.

The European patent grants coverage of the Weight Management Genetic Test into 2029. Corresponding patents have been granted in major markets including Eurasia, Japan, Mexico, Russia and New Zealand. Patent applications are pending in the United States and other major markets.

Regarding its PerioPredict®, the company is continuing to work with its partner, Employee Benefits Consulting Group (EBCG) to develop and put into place prevention programs that target members at-risk for or diagnosed with diabetes, cardiovascular disease and other inflammatory mediated conditions who will benefit from increased dental preventive care. Interleukin is also expanding its activities with medical and dental carriers to initiate demonstration programs that could lead to wider program adoption.

 

 

 

The QualityStocks
Newsroom

Read the articles covering the biggest movers in the markets today.

Continue

Market
Basics

Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks markets.

Continue

The QualityStocks Daily
Archives

Go back to see our previous newsletters and find out what you might have missed.

Continue